EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan

Daichi Sugahara, Keiko Nemoto Murofushi, Hideomi Yamashita iD, Etsuyo Ogo iD, Koyo Kikuchi iD, Anneyuko I Saito, Takafumi Komiyama, Nobuki Imano iD, Ataru Igarashi iD, Sayaka Ohno, Hiroshi Onishi iD

Japanese Journal of Clinical Oncology · 05.08.2026 · 56 (8) · 984-992

DOI: 10.1093/jjco/hyag063 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 05.06.2026. Verfasst von Daichi Sugahara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The University of Tokyo Hospital,113-8655, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Chemoradiotherapy. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japanese Society for Radiation Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to evaluate real-world clinical outcomes and prognostic factors of definitive chemoradiotherapy (CRT) for bladder cancer in Japan.

Methods

Patients with bladder cancer treated with definitive CRT between 2010 and 2023 at seven Japanese institutions were retrospectively analyzed. Overall survival (OS) was estimated using the Kaplan–Meier method, whereas cause-specific survival (CSS) and bladder preservation were analyzed using competing risk methods. Univariable analyses were performed using the log-rank and Gray’s tests, and multivariable analyses were performed using Cox and Fine-Gray models with Bayesian Information Criterion-based stepwise selection.

Results

A total of 175 patients were included. Maximal transurethral resection of the bladder tumor (TUR-Bt) was performed in 55% of patients, and 49% were deemed ineligible for radical cystectomy (RC). The 5-year OS, CSS, and bladder preservation rate were 52% (95% CI, 42–60%), 73% (95% CI, 66–80%), and 69% (95% CI, 61–77%), respectively. In multivariable analyses, poorer performance status remained associated with worse OS (P = .003), whereas advanced clinical T stage was associated with worse CSS (P = .018) and maximal TUR-Bt was associated with improved bladder preservation (P = .024). Although patients ineligible for RC demonstrated inferior OS (P < .001) and CSS (P = .007) in univariable analyses, bladder preservation was comparable to those treated by patient preference.

Conclusions

This multi-institutional retrospective study demonstrates acceptable real-world outcomes of definitive CRT for bladder cancer in Japan. Patient-related factors influenced OS, whereas tumor burden and local tumor control were associated with CSS and bladder preservation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsChemoradiotherapyHumansRetrospective StudiesFemaleAgedJapanMaleMiddle AgedTreatment OutcomeAged, 80 and overPrognosisTransurethral Resection of BladderCystectomy

Stichwörter der Autor:innen

Chemoradiotherapyorgan preservationurinary bladder neoplasms

Autor:innen und Institutionen

  • Department of Radiology, The University of Tokyo Hospital,113-8655, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan.
  • Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-8677, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, Japan.
  • Radiation Oncology Center, Kurume University, 830-0011, 67, Asahi-cho, Kurume, Fukuoka, Japan.
  • Department of Radiation Oncology, Iwate Medical University Hospital, 028-3695, 2-1-1, Idai-dori, Yahaba-cho, Shiwa-gun, Iwate, Japan.
  • Division of Radiation Oncology, Department of Radiology, Juntendo University Urayasu Hospital, 279-0021, 2-1-1, Tomioka, Urayasu, Chiba, Japan.
  • Department of Radiology, University of Yamanashi, 409-3898, 1110, Shimokato, Chuo, Yamanashi, Japan.

ORCID-Profile: Hideomi Yamashita, Etsuyo Ogo, Koyo Kikuchi, Nobuki Imano, Ataru Igarashi, Hiroshi Onishi

Förderung

  • Japanese Society for Radiation Oncology

Zitieren

APA

Sugahara, D., Murofushi, K. N., Yamashita, H., Ogo, E., Kikuchi, K., Saito, A. I., Komiyama, T., Imano, N., Igarashi, A., Ohno, S., & Onishi, H. (2026). Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan. Japanese Journal of Clinical Oncology, 56(8), 984-992. https://doi.org/10.1093/jjco/hyag063

Vancouver

Sugahara D, Murofushi KN, Yamashita H, Ogo E, Kikuchi K, Saito AI, et al. Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan. Japanese Journal of Clinical Oncology. 2026;56(8):984-992. doi:10.1093/jjco/hyag063

BibTeX
@article{Sugahara2026,
  author = {Sugahara, Daichi and Murofushi, Keiko Nemoto and Yamashita, Hideomi and Ogo, Etsuyo and Kikuchi, Koyo and Saito, Anneyuko I and Komiyama, Takafumi and Imano, Nobuki and Igarashi, Ataru and Ohno, Sayaka and Onishi, Hiroshi},
  title = {Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2026},
  volume = {56},
  number = {8},
  pages = {984--992},
  doi = {10.1093/jjco/hyag063}
}
Kostenlos starten →